• 1401/08/01 - 15:00
  • تعداد بازدید خبر : 379
  • زمان مطالعه: 1 دقیقه
مقاله چاپ شده اعضای مرکز در مهر 1401-2

مقاله چاپ شده اعضای مرکز تحقیقات بیماریهای کودکان در مهر 1401-2

مقاله چاپ شده اعضای مرکز در مهر 1401 در مجله Iranian Journal of Blood and Cancer

مقاله چاپ شده اعضای مرکز در مهر 1401 در مجله Iranian Journal of Blood and Cancer
Authors
Bahram Darbandi, Parham Niyasti, Shohreh Maleknejad, Adel Baghersalimi, Houman Hashemian, Arezoo Karimzadeh
Publication date
2022/6/10
Journal
Iranian Journal of Blood and Cancer
Volume
14
Issue
2
Pages
49-57
Publisher
Iranian Journal of Blood and Cancer
Description
Cytomegalovirus, a member of herpesviridae family, is a double-stranded DNA virus [1, 2] which can be a leading cause of viral-associated congenital infections [3] or either can be acquired [1]. Between 50 to 80 percent of the world’s population is seropositive for CMV [4]. Most clinical disease occurs in individuals previously infected with CMV (seropositive) and therefore represents either re-activation of latent infection or re-infection (de novo) with a novel strain [5]. In immunocompetent host, it is typically asymptomatic or is responsible for mild undifferentiated viral symptoms and mononucleosislike syndrome [4]. Rarely, serious CMV infection has occurred in individuals with healthy immune system [6]. In contrast to immuno-competent patients, immuno-compromised patients may experience systemic and end-organ disease primarily due to virus reactivation as a result of impaired immune system consistency. Systemic CMV disease is characterized by fever, pancytopenia, and inflammatory changes in multiple organs [4].
CMV infection is controlled by virus-specific CD4+ and CD8+ cytotoxic T-lymphocytes [7]. Previously, it was demonstrated that conditions like HIV infection, hematopoietic stem cell transplantation (HSCT), solid organ transplantation [8], and some immunosuppressive agents like ibrutinib [9], dasatinib [4], alemtuzumab [10], steroids, fludarabin, and high-dose cyclophosphamide [11] can impair T-cell mediated immunity but standard chemotherapy alone for pediatric leukemia mainly depletes humoral rather than cellular immunity [12]. Therefore, CMV disease development is rare in pediatric non-HSCT ALL being on chemotherapy …
  • گروه خبری : گروه های مطالب,اخبار مرکز تحقیقات کودکان,pediatrics news,اخبار اختصاصی,اطلاعیه ها,رویدادها,گزارش های تصویری
  • کد خبر : 94554
کلمات کلیدی
مدیر سایت
خبرنگار

مدیر سایت

تعداد نظرات

0 نظر برای این مطلب وجود دارد

نظر دهید

آخرین بروز رسانی : 1401/08/01 15:00